OSL · TRMED.OL
Thor Medical ASA
NOK 4.15-NOK 0.07 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
Loading market information…
OSL · GENT.OL · NOK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 03:25 PM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
Gentian Diagnostics AS’s quoted price sits in the lower half of its reported 52-week range, 35.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Gentian Diagnostics AS’s forward annual dividend is NOK 0.60 per share, paid annual. The forward yield is 1.55% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Gentian Diagnostics AS’s next earnings report is currently expected on Feb 18, 2027, with estimated earnings per share of -NOK 0.32. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gentian Diagnostics AS’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 7, 2025 |
| NOK 0.49 |
| NOK 44.50M |
| Q4 2024 | Feb 12, 2025 | NOK 2.09 | NOK 42.61M |
|---|
| Q3 2024 | Sep 29, 2024 | NOK 0.21 | NOK 32.70M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 4.15-NOK 0.07 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
NOK 3.06+NOK 0.04 (+1.16%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.25% below the high.
NOK 7.74+NOK 0.24 (+3.2%)
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
NOK 1.30NOK 0.00 (0.0%)
Hofseth BioCare ASA’s quoted price sits in the lower half of its reported 52-week range, 37.14% below the high.
NOK 4.37-NOK 0.13 (-2.89%)
ContextVision AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 24.39% below the high.
NOK 11.25+NOK 0.25 (+2.27%)
Navamedic ASA’s quoted price sits in the lower half of its reported 52-week range, 57.55% below the high.
NOK 0.44+NOK 0.01 (+2.69%)
Lifecare AS’s quoted price sits in the lower half of its reported 52-week range, 92.81% below the high.
NOK 5.00-NOK 0.20 (-3.85%)
CodeLab Capital AS’s quoted price sits in the upper half of its reported 52-week range, 18.83% below the high.
